VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
BL, baseline a Total anemia response = transfusion independence (TI) in pts with BL Hb<10 g/dl with Hb increase ≥ 2g/dl + TI in those who were transfusion-dependent at BL. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results